| New Challenges to Elastomeric ClosuresClaudia Petersen West Pharmaceutical Services Deutschland GmbH, Technical           Customer Service Department, Eschweiler (Germany) Regulatory bodies worldwide are requesting extensive           information on elastomeric closures used as primary packaging for drugs           and biologics. The information requested often includes the chemical and           physical properties and cleanliness of elastomers. Several factors are           contributing to these requests. They include:  1. the need for extractable studies on the container/closure           systems;2. the need for leachable studies with the           drug product as extraction medium;
 3. the need for chemically clean pack-aging components used for highly           sensitive biological/biotechnology derived products; chemical cleanliness           relates to a low potential of extractable sub-stances from elastomeric           closures.
 Each factor is significant in establishing the safety           and efficacy of the drug or biologic product during the approval process           and in establishing the shelf-life of the product. These compounds, which           are effective i n very low dosages, are often lyophilized. The resulting           small cakes require lyophilization stoppers that are chemically clean,           low in residual moisture content and low in moisture vapor transmission.The recommendations for more information have been driven in part by the           United States Food and Drug Administration (FDA) Guidance for Industry           Container Closure Systems for Packaging Human Drugs and Biologics           (issued May 1999) and the International Conference on Harmonisation (ICH)           Q3A and ICH Q3B(R) Impurities in New Drug Substances. Closure           integrity recommendations have also become more stringent, per the FDA           Draft Guidance for Industry Container and Closure Integrity Testing           IN LIEU of Sterility Testing as a component of the stability protocol           for sterile products. This is a draft guidance that has not been           officially accepted or issued by the FDA; FDA sources indicate it may           be incorporated into the final FDA stability guidance if and when it is           issued. The 1999 container closure recommendation for performance of the           system addresses seal integrity, which also relates to the performance           criteria for the closure system. Seal integrity is influenced by factors           such as the rubber formulation, design, processing, package assembly and           storage conditions. All factors have to be taken into consideration to           improve the overall container closure performance.
 The article will give an overview of what has been done to improve processes,           formulations and designs to fulfill these demands for quality packaging           components and whether United States and European regulatory bodies opinions           differ.
 Key Words Elastomeric closures, extractables,           leachables · Helium leakage testing · Seal integrity |